Pacific Edge is a global cancer diagnostics company that specializes in developing diagnostic and prognostic tools for cancer. Established in 2001, their mission is to provide easy-to-use, non-invasive, and highly accurate tests for cancer detection and surveillance. Their focus is on bladder cancer products, although they also cover other cancer types such as gastric, colorectal, endometrial, and melanoma.

Pacific Edge's flagship product is Cxbladder, a next-generation genomic biomarker test for the detection and surveillance of bladder cancer. This test offers a significant improvement in accuracy compared to other urine-based cancer tests, revolutionizing the standard of care. With certified laboratories in New Zealand and the United States, Pacific Edge can provide commercial services to clinicians and process urine samples.

Operating on a franchise-like business model, they target specific geographies and markets where their products can be readily adopted at scale. Pacific Edge is at the forefront of advancing cancer diagnosis and improving patient care